• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
Oct 12, 2015 7:00am EDT

VolitionRx Announces Publication of Results from Pancreatic Cancer Study with Lund University in Clinical Epigenetics

Sep 22, 2015 7:00am EDT

VolitionRx Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

Sep 10, 2015 7:00am EDT

VolitionRx Granted Its First U.S. Patent

Sep 09, 2015 8:00am EDT

VolitionRx Demonstrates NuQ(R) Blood Test Detects 81% of Colorectal Cancers and 67% of High Risk Adenomas in Large Double Blinded Clinical Trial

Sep 02, 2015 8:00am EDT

VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015

Sep 01, 2015 8:00am EDT

VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015

Aug 17, 2015 8:00am EDT

VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer

Aug 11, 2015 6:30am EDT

VolitionRx Announces Second Quarter 2015 Financial Results and Business Update

Aug 05, 2015 8:00am EDT

VolitionRx Schedules Second Quarter 2015 Earnings Conference Call and Business Update for Tuesday, August 11, 2015 at 8:30am ET

Aug 03, 2015 8:00am EDT

VolitionRx to Present at Wedbush PacGrow Healthcare Conference

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.